What the research found
The Biomarkers of Aging Consortium is hosting a major conference in October 2026 bringing together researchers, clinicians, regulators, and industry leaders to address a critical bottleneck: aging-targeting therapies are moving toward clinical trials, but the field lacks standardized, validated ways to measure biological aging or confirm that a treatment actually slows it. Rather than presenting new experimental findings, this gathering aims to establish consensus around how aging biomarkers should be validated and what they reliably indicate about human biology.
The program spans multiple approaches to measuring aging—from epigenetic clocks (which infer biological age from DNA methylation patterns) to systems-level and AI-driven models, multi-omic profiling, and immune/cellular markers. Sessions will also cover how these tools move from research into regulatory approval and clinical decision-making, with input from funding agencies, the FDA, and companies developing aging-focused therapies.
Why it matters for you
If you're tracking biomarkers and considering longevity interventions—whether peptides, hormones, supplements, or lifestyle changes—you're relying on measurements that the field itself is still standardizing. Right now, different labs may report "biological age" using different clocks or methods, making it hard to know if your protocol actually works. This conference represents an effort to solve that problem: establishing which biomarkers are trustworthy predictors of lifespan or healthspan, how they should be measured, and what changes in them actually mean.
For MyKine users specifically, this affects how meaningful your tracked metrics are. Epigenetic clocks (like DunedinPACE) are increasingly available through consumer testing, but without consensus on validation, it's unclear whether a 1-year drop in "biological age" reflects real physiological improvement or measurement noise. Similarly, if you're using immune markers, inflammatory panels, or other aging-related biomarkers to guide your protocols, the standardization work underway could eventually give those numbers clearer clinical weight—or reveal which ones are less reliable than marketed.
Caveats
- This is a conference announcement, not a research finding—no new data is presented here.
- The field's current lack of standardized validation means existing commercial aging biomarkers (including epigenetic clocks) may not yet meet rigorous clinical standards.
- Most aging biomarker work to date is still observational or correlational; causality between biomarker changes and actual lifespan extension in humans remains unproven.
- Regulatory pathways for aging as a therapeutic target are still being shaped—approval frameworks don't yet exist.